Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

MELBOURNE, Australia, June 23, 2020 (GLOBE NEWSWIRE) — Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.
To register for the free webinar, please visit: Genetic Technologies LimitedGenetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.Genetic Technologies has capacity for COVID-19 testing and is developing a pipeline of risk assessment products.For more information, please visit 
Dave Gentry, CEO
RedChip Companies
Office: 1 800 RED CHIP (733 2447)
Cell: US 407 491 4498
[email protected] 

Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search